BofA hikes MSFT target to $600 on Azure AI acceleration
Sep 1, 2026, 11:27 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Analyst upgrade and higher PT, coupled with AI-driven Azure growth, can attract new money and extend the rally in the near term; positive earnings signals historically lead to multiple expansion for large-cap tech names like MSFT.
AI summary
What happened, with direct paths to the underlying reporting
Bank of America raises Microsoft’s price target to $600 on accelerating Azure growth tied to its AI strategy, citing 43% Azure expansion in 4Q26 and 1Q27 guidance of 45%. The note reinforces AI-driven upside alongside Nvidia financing momentum and investor Ackman’s MSFT stake, suggesting continued near-term upside as AI infrastructure demand supports MSFT's cloud momentum.
BofA raises MSFT target to $600; maintains Buy on AI-driven growth.
Azure growth accelerates: 39% in 3Q26 to 43% in 4Q26.
Guidance for 1Q27 at 45% reinforces durable AI-driven cloud demand.
Nvidia's AI financing signals AI infra momentum across industry.
Ackman's MSFT stake adds sentiment support amid rally.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
BNP Paribas remains positive on MSFT, maintaining an Outperform rating with a $604 price target. The firm highlights stronger Copilot enterprise deployments, the new E7 bundle, an…
Microsoft is due to report after the close on Wednesday, with traders braced for a move that could push MSFT toward its latest peak. The result will influence near-term price acti…
Microsoft researchers published a Science study showing an AI diagnostic tool performs stepwise clinical reasoning and is more than twice as accurate as general physicians in comp…
Microsoft's DxO AI system correctly diagnosed 83% of complex medical cases, far above 36% by generalists. The Mayo Clinic partnership and Beth Israel Deaconess evaluations aim to…